Psychopharmacology

, Volume 52, Issue 2, pp 137–144 | Cite as

Neurochemical investigations of the interaction of N,N-dimethyltryptamine with the dopaminergic system in rat brain

  • P. C. Waldmeier
  • L. Maître
Animal Studies

Abstract

N,N-dimethyltryptamine (DMT) is a psychotomimetic indolealkylamine that has been suspected of being an endogenous causal factor in the aetiology of schizophrenia. Some aspects of its interaction with the dopaminergic system of the rat brain have been studied neurochemically, and comparisons have been made with the effects of d-amphetamine and apomorphine. In contrast to these two compounds, DMT has proved to be a potent, but short-acting MAO inhibitor with a rather selective effect on MAO A (serotonin-deaminating MAO).

Like classical MAO inhibitors, DMT also greatly increases the accumulation of 3H-dopamine plus 3H-3-methoxytyramine newly formed from 3H-Dopa. Amphetamine and apomorphine have no comparable effect.

Striatal levels of 3,4-dihydroxyphenylacetic acid are more efficiently lowered by DMT than those of homovanillic acid. the reverse has been observed with apomorphine, whereas amphetamine increases the concentrations of homovanillic acid and decreases those of 3,4-dihydroxyphenylacetic acid.

Thus, in addition to its MAO inhibitory action, DMT probably also possesses dopamine-releasing effects. Both these properties could result in an indirect dopaminomimetic activity of DMT. It may be assumed, therefore, that the psychotomimetic activity of this compound is not noly linked to its effects on cerebral serotonergic mechanisms, but to a combination of these with an indirect dopaminergic stimulant activity.

Key words

Dimethyltryptamine Monoamine oxidase inhibition Dopamine metabolism Homovanillic acid 3,4-Dihydroxyphenylacetic acid Dopamine release 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andén, N. E., Corrodi, H., Fuxe, K.: Hallucinogenic drugs of the indolealkylamine type and central monoamine neurons. J. Pharmacol. exp. Ther. 179, 236–249 (1971)Google Scholar
  2. Andén, N. E., Corrodi, H., Fuxe, K., Hökfelt, T.: Evidence for a central 5-hydroxytryptamine receptor stimulation by lysergic acid diethylamide. Brit. J. Pharmacol. 34, 1–7 (1968)Google Scholar
  3. Andén, N. E., Roos, B. E., Werdinius, B.: The occurrence of homovanillic acid in brain and cerebrospinal fluid and its determination by a fluorometric method. Life Sci. 7, 448–458 (1963)Google Scholar
  4. Andén, N. E., Rubenson, A., Fuxe, K., Hökfelt, T.: Evidence for dopamine receptor stimulation by apomorphine. J. Pharm. Pharmacol. 19, 627–629 (1967)Google Scholar
  5. Atack, C. V., Magnusson, T.: Individual elution of noradrenaline (together with adrenaline) dopamine, 5-hydroxytryptamine and histamine from a single, strong cation exchange column, by means of mineral acid-organic solvent mixtures. J. Pharm. Pharmacol. 22, 625–627 (1970)Google Scholar
  6. Axelrod, J.: the enzymatic methylation of serotonin and other amines. J. Pharmacol. exp. Ther. 138, 28–33 (1962)Google Scholar
  7. Banerjee, S. P., Snyder, S. H.: Methyltertrahydrofolic acid mediates N- and O-methylation of biogenic amines. Science 182, 74–75 (1973)Google Scholar
  8. Bradley, P. B., Briggs, I.: Further studies on the mode of action of psychotomimetic drugs: antagonism of the excitatory actions of 5-hydroxytryptamine by methylated derivatives of tryptamine. Brit. J. Pharmacol. 50, 345–354 (1974)Google Scholar
  9. Braestrup, C., Andersen, H., Randrup, A.: The monoamine oxydase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation. Europ. J. Pharmacol. 34, 181–187 (1975)Google Scholar
  10. Carlsson, A.: Receptor-mediated control of dopamine metabolism. In: Pre- and postsynaptic receptors, E. Usdin and W. E. Bunney, eds., pp. 49–63. New York: Dekker 1975Google Scholar
  11. Da Prada, M., Saner, A., Burkard, W. P., Bartholini, G., Pletscher, A.: Lysergic acid diethylamide: evidence for stimulation of cerebral dopamine receptors. Brain Res. 94, 67–73 (1975)Google Scholar
  12. Di Chiara, G., Balakleevsky, A., Porceddu, M. L., Tagliamonte, A., Gessa, G. L.: Inhibition by apomorphine of dopamine deamination in the rat brain. J. Neurochem. 23, 1105–1108 (1974)Google Scholar
  13. Fabing, H. D.: The dimensions of neurology. Neurology (Mineap.) 5, 603–611 (1955)Google Scholar
  14. Fuentes, J. A., Del Rio, J.: Striatal homovanillic acid levels in rats after combined treatments with amphetamine and neuroleptics. Europ. J. Pharmacol. 17, 297–300 (1972)Google Scholar
  15. Gilka, L.: Schizophrenia: a disorder of tryptophan metabolism. Acta psychiat. scand., Suppl. 258, 1–83 (1975)Google Scholar
  16. Glowinski, J., Axelrod, J., Iversen, L. L.: Regional studies of catecholamines in the rat brain. IV. Effect of drugs on the disposition and metabolism of 3H-norepinephrine and 3H-dopamine. J. Pharmacol. exp. Ther. 153, 30–41 (1966)Google Scholar
  17. haigler, H. J., Aghajanian, G. K.: Lysergic acid diethylamide and serotonin: a comparison of effects on serotonergic neurons and neurons receiving a serotonergic input. J. Pharmacol. exp. Ther. 188, 688–699 (1974)Google Scholar
  18. Hsu, L. L., Mandell, A. J.: Multiple N-methyltransferases for aromatic alkylamines in brain. Life Sci. 13, 847–858 (1973)Google Scholar
  19. Hsu, L. L., Mandell, A. J.: Enzymatic formation of tetrahydro-β-carboline from tryptamine and 5-methyltetrahydrofolic acid in rat brain fractions: regional and subcellular distribution. J. Neurochem. 24, 631–636 (1975)Google Scholar
  20. Jori, A., Bernardi, D.: Further studies on the increase of striatal homovanillic acid induced by amphetamine and fenfluramine. Europ. J. Pharmacol. 19, 276–280 (1972)Google Scholar
  21. Jori, A., Dolfini, E., Tognoni, G., Garattini, S.: Differential effects of amphetamine, fenfluramine, and norfenfluramine stereoisomers on the increase of striatum homovanillic acid in rats. J. Pharm. Pharmacol. 25, 315–318 (1973)Google Scholar
  22. Kelly, P. H., Iversen, L. L.: LSD as an agonist at mesolimbic dopamine receptors. Psychopharmacologia (Berl.) 45, 221–224 (1975)Google Scholar
  23. Langelier, P., Parent, A., Poirier, L. J.: Decarboxylase activity of the brain capillary walls and parenchyma in the rat, cat and monkey. Brain Res. 45, 622–629 (1972)Google Scholar
  24. Laverty, R., Sharman, D. F.: Modification by drugs of the metabolism of 3,4-dihydroxyphenethylamine. Brit. J. Pharmacol. 24, 759–772 (1965)Google Scholar
  25. Leysen, J., Laduron, P.: N-Methylation of indolealkylamines in the brain with a new methyl donor. In: Adv. biochem. psychopharmacol., Vol. 11, E. Costa, G. L. Gessa, and M. Sandler, eds., pp. 65–74. New York: Raven Press 1974aGoogle Scholar
  26. Leysen, J., Laduron, P.: Characterization of an enzyme yielding formaldehyde from 5-methyltetrahydrofolic acid. FEBS Letters 47, 299–303 (1974b)Google Scholar
  27. Lu, L. W., Wilson, A., Moore, R. H., Domino, E. F.: Correlation between brain N,N-dimethyltryptamine levels and bar pressing behavior in rats: effect of MAO inhibition. Pharmacologist 16, 237 (1974)Google Scholar
  28. Maître, L., Delini-Stula, A., Waldmeier, P. C.: Relations between the degree of monoamine oxidase inhibition and some psychopharmacological responses to monoamine oxidase inhibitors in rats. Ciba Found. Symp. on “Monoamine oxidase and its inhibition”, pp. 247–267. Amsterdam-Oxford-New York: Elsevier 1976Google Scholar
  29. Mandel, L. R., Rosegay, A., Walker, R. W., Vandenheuvel, W. J. A.: 5-Methyltetrahydrofolic acid as a mediator in the formation of pyridoindoles. Science 186, 741–743 (1974)Google Scholar
  30. Meller, E., Rosengarten, H., Friedhoff, A. J.: Conversion of 14C-S-adenosylmethionine to 14C-formaldehyde and condensation with indoleamines: a side-reaction in N-methyltransferase assay in blood. Life Sci. 14, 2167–2178 (1974)Google Scholar
  31. Moore, R. H., Demetriou, S. K., Domino, E. F.: Effects of iproniazid, chlorpromazine and methiothepin on DMT-induced changes in body temperature, pupillary dilatation, blood pressure and EEG in the rabbit. Arch. int. Pharmacodyn. 213, 64–72 (1975)Google Scholar
  32. Murphy, G. F., Robinson, D., Sharman, D. F.: The effect of tropolone on the formation of 3,4-dihydroxyphenylacetic acid and 4-hydroxy-3-methoxyphenylacetic acid in the brain of the mouse. Brit. J. Pharmacol. 36, 107–115 (1969)Google Scholar
  33. Roffler-Tarlov, S., Sharman, D. F., Tegerdine, P.: 3,4-dihydroxyphenylacetic acid and 4-hydroxy-3-methoxyphenylacetic acid in the mouse striatum: a reflection of intra- and extraneuronal metabolism of dopamine. Brit. J. Pharmacol. 42, 343–351 (1971)Google Scholar
  34. Saavedra, J. M., Axelrod, J.: Psychotomimetic N-methylated tryptamines: formation in brain in vitro and in vivo. Science 175, 1365–1366 (1972)Google Scholar
  35. Sharman, D. F.: Methods of determination of catecholamines and their metabolites. In: Methods of neurochemistry, Vol. 1, R. Fried, ed., pp. 83–127. New York: Dekker 1971Google Scholar
  36. Smith, T. L.: Some neurochemical effects of N,N-dimethyltryptamine and their possible relation to acute schizophrenia. Thesis, Reno, Nev. U.S.A. 1975; Dissertation Abst. Intern. B 35, 4374 B–4375 B (1975)Google Scholar
  37. Szara, S.: Dimethyltryptamine: its metabolism in man: the relation of its psychotic effect to the serotonin metabolism. Experientia (Basel) 12, 441–442 (1956)Google Scholar
  38. Von Hungen, K., Roberts, S., Hill, D. F.: Interactions between lysergic acid diethylamide and dopamine-sensitive adenylate cyclase systems in rat brain. Brain Res. 94, 57–66 (1975)Google Scholar
  39. Waldmeier, P. C., Delini-Stula, A., Maître, L.: Preferential deamination of dopamine by an A-type monoamine oxidase in rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 292, 9–14 (1976)Google Scholar
  40. Waldmeier, P. C., Maître, L.: Comparison of short and long-lasting effects of pargyline on cerebral dopamine metabolism. Naunyn-Schmiedeberg's Arch. Pharmacol. 294,133–140 (1976)Google Scholar
  41. Wurtman, R. J., Axelrod, J.: A sensitive and specific assay for the estimation of monoamine oxidase. Biochem. Pharmacol. 12, 1439–1441 (1963)Google Scholar

Copyright information

© Springer-Verlag 1977

Authors and Affiliations

  • P. C. Waldmeier
    • 1
  • L. Maître
    • 1
  1. 1.Department Forschung, Division PharmaCiba-Geigy AGBaselSwitzerland

Personalised recommendations